Durect
Durect is a biopharmaceutical company that develops epigenetic therapeutics for serious conditions such as acute organ injury and cancer, and offers advanced drug delivery technologies.
Services
Durect develops epigenetic therapeutics for serious and life-threatening conditions, including acute organ injury and cancer. The company focuses on targeting dysregulated DNA methylation. Additionally, Durect offers drug delivery technologies, including long-acting injectables using proprietary SABER® and CLOUD™ platforms. Their range also includes the ALZET Osmotic Pumps, marketed for experimental research in laboratory animals. These services support Durect’s mission to enhance medical outcomes through innovative technology and therapeutic approaches.
Products
Durect's product portfolio includes POSIMIR® (bupivacaine solution), which is FDA-approved for post-surgical pain and licensed to Innocoll Pharmaceuticals for U.S. commercialization. The company also markets ALZET Osmotic Pumps globally for experimental research in laboratory animals. Durect’s proprietary drug delivery platforms, SABER® and CLOUD™, support the development of long-acting injectable products. These products exemplify Durect’s commitment to advancing drug delivery technologies and therapeutic solutions for various medical conditions.
Lead Epigenetic Modulator: Larsucosterol
Durect's lead epigenetic modulator, larsucosterol, targets dysregulated DNA methylation to treat acute organ injury and chronic liver disease. Larsucosterol is under evaluation for treating alcohol-associated hepatitis (AH) and has received FDA Fast Track Designation. The company completed a Phase 2b study (AHFIRM) in patients with severe alcohol-associated hepatitis across multiple countries, including the U.S., EU, U.K., and Australia. Larsucosterol represents a promising candidate in Durect’s pipeline for combating serious liver conditions.
Drug Delivery Technologies
Durect offers innovative drug delivery technologies through their proprietary SABER® and CLOUD™ platforms, aimed at developing long-acting injectable products. The SABER® platform supports extended-release formulations that can improve patient compliance and therapeutic outcomes. The CLOUD™ platform is designed for sustained drug release, enhancing the efficacy of treatment regimens. Additionally, Durect markets ALZET Osmotic Pumps worldwide, which are used in experimental research involving laboratory animals. These technologies highlight Durect’s commitment to advancing drug delivery methods.
Clinical Research and Development
Durect conducts extensive clinical research and development to bring innovative therapeutics to market. The company has completed a Phase 2b study (AHFIRM) for their lead epigenetic modulator, larsucosterol, in patients with severe alcohol-associated hepatitis. This study was conducted across the U.S., EU, U.K., and Australia. Additionally, Durect engages in strategic partnerships to further drug development and commercialization, leveraging their expertise in epigenetic therapeutics and drug delivery technologies. This focus on clinical research underscores Durect’s dedication to advancing medical science.